title: Cyclosporine-induced autologous graft-versus-host disease following autologous blood stem cell transplantation for lymphoma.
abstract: Eight consecutive patients with relapsed/refractory non-Hodgkin's lymphoma or Hodgkin's disease received conditioning therapy with BCNU, etoposide, cytosine arabinoside and melphalan (BEAM) followed by autologous blood stem cell transplantation (ABSCT). Cyclosporine was administered from day +1 until day +28 post-ABSCT to induce autologous graft-versus-host disease (GVHD) for a possible antitumor effect. Three patients developed histologically documented grade II GVHD between 22-40 days post-transplant. GVHD resolved with local hydrocortisone 1% application in one patient and after a short course of steroid in the remaining two patients. Further studies are required to document any beneficial antitumor effect of such therapy following ABSCT.
authors.affiliation: Division of Transplantation Medicine, Richland Memorial Hospital, University of South Carolina, Columbia, USA.
authors.forename: A R
authors.initials: AR
authors.lastname: Pati
authors.forename: K T
authors.initials: KT
authors.lastname: Godder
authors.forename: S H
authors.initials: SH
authors.lastname: Abhyankar
authors.forename: A P
authors.initials: AP
authors.lastname: Gee
authors.forename: P J
authors.initials: PJ
authors.lastname: Henslee-Downey
mesh_terms: D000328:Adult; D016572:Cyclosporine / Q000494:pharmacology*; D005260:Female; D006086:Graft vs Host Disease / Q000139:chemically induced*; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D008223:Lymphoma / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D014182:Transplantation, Autologous
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine